




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B





FIG. 3A



gB		
	E _{max}	%Relative Potency gB
Equal Mass Formulation	2.05	74%
Molar-based formulation with 2X gH and 2X gB	2.8	100%

FIG. 3B




FIG. 4




FIG. 5





FIG. 6A






FIG. 6B



* equal molar of all 6 components would have dosed gH at 279 ng

FIG. 6C

10/31



Note: equal molar of all 6 components would have dosed UL131A at 74 ng

FIG. 6D




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9A





FIG. 9B






FIG. 11




FIG. 12





FIG. 13



- A. Lot #5 (pre-lyo): Values vs Concentration } Weighting: Fixed
- B. Lot #6 (pre-lyo): Values vs Concentration } Weighting: Fixed
- C. Lot #7 (pre-lyo): Values vs Concentration } Weighting: Fixed

FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23





FIG. 24



Note: Saliva collection should be performed at least 90 minutes after the last breast feeding.

FIG. 25